Integra LifeSciences Holdings Management
Management criteria checks 4/4
Integra LifeSciences Holdings' CEO is Jan De Witte, appointed in Dec 2021, has a tenure of 3.08 years. total yearly compensation is $6.39M, comprised of 13.7% salary and 86.3% bonuses, including company stock and options. directly owns 0.031% of the company’s shares, worth $542.17K. The average tenure of the management team and the board of directors is 3.8 years and 11.7 years respectively.
Key information
Jan De Witte
Chief executive officer
US$6.4m
Total compensation
| CEO salary percentage | 13.7% |
| CEO tenure | 3.1yrs |
| CEO ownership | 0.03% |
| Management average tenure | 3.8yrs |
| Board average tenure | 11.7yrs |
Recent management updates
Recent updates
There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise
Nov 05
Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Oct 24Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S
Sep 08Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?
Aug 21At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?
Jul 01Integra LifeSciences Still Underperforming As Manufacturing Issues Linger
Jun 21Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price
May 28Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled
Feb 27We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Feb 11Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jan 14Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings
Dec 31Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?
Dec 03Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?
Nov 06Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns
Oct 24Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Sep 22Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?
Aug 15Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes
Jul 03Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jun 19Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
May 05These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well
Apr 07Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital
Mar 26At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?
Mar 14Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?
Feb 27Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
Feb 02We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Jan 05Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return
Dec 21When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Dec 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$7m |
| Jun 30 2024 | n/a | n/a | US$24m |
| Mar 31 2024 | n/a | n/a | US$40m |
| Dec 31 2023 | US$6m | US$875k | US$68m |
| Sep 30 2023 | n/a | n/a | US$101m |
| Jun 30 2023 | n/a | n/a | US$131m |
| Mar 31 2023 | n/a | n/a | US$172m |
| Dec 31 2022 | US$9m | US$850k | US$181m |
| Sep 30 2022 | n/a | n/a | US$173m |
| Jun 30 2022 | n/a | n/a | US$166m |
| Mar 31 2022 | n/a | n/a | US$157m |
| Dec 31 2021 | US$899k | US$59k | US$169m |
Compensation vs Market: Jan's total compensation ($USD6.39M) is about average for companies of similar size in the US market ($USD5.43M).
Compensation vs Earnings: Jan's compensation has been consistent with company performance over the past year.
CEO
Jan De Witte (60 yo)
3.1yrs
Tenure
US$6,388,756
Compensation
Mr. Jan De Witte has been President, Chief Executive Officer & Director of Integra LifeSciences Holdings Corporation since December 1, 2021. He had been the Chief Executive Officer at Barco NV since Septem...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 27.1yrs | US$422.52k | 2.27% $ 39.8m | |
| President | 3.1yrs | US$6.39m | 0.031% $ 542.2k | |
| Executive VP & CFO | 1.6yrs | US$1.67m | 0.054% $ 951.2k | |
| Senior VP of Finance & Principal Accounting Officer | 7.3yrs | US$1.25m | 0.047% $ 818.5k | |
| Executive VP | 6.2yrs | US$1.62m | 0.077% $ 1.3m | |
| Executive VP & President of Tissue Technologies | 12.1yrs | US$1.42m | 0.084% $ 1.5m | |
| Executive VP & President of Codman Specialty Surgical | 4.7yrs | US$2.83m | 0.073% $ 1.3m | |
| Corporate VP of Global Operations & Supply Chain | 4.4yrs | no data | no data | |
| Vice President of Global Corporate Communications & Public Relations | no data | no data | no data | |
| Vice President of Global Marketing | no data | no data | no data | |
| Executive VP & Chief Human Resources Officer | 2yrs | no data | 0.032% $ 552.8k | |
| Corporate VP & Chief Digital Officer | 3yrs | no data | no data |
3.8yrs
Average Tenure
58yo
Average Age
Experienced Management: IART's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 27.1yrs | US$422.52k | 2.27% $ 39.8m | |
| President | 3.1yrs | US$6.39m | 0.031% $ 542.2k | |
| Independent Director | 15.8yrs | US$297.54k | 0.11% $ 1.9m | |
| Independent Director | 19yrs | US$293.28k | 0.082% $ 1.4m | |
| Independent Presiding Director | 11.7yrs | US$342.54k | 0.18% $ 3.1m | |
| Independent Director | 33yrs | US$306.31k | 0.091% $ 1.6m | |
| Independent Director | 1.1yrs | US$90.68k | 0.016% $ 283.3k | |
| Independent Director | 3.8yrs | US$260.04k | 0.028% $ 497.2k | |
| Independent Director | 2.5yrs | US$297.54k | 0.021% $ 366.3k |
11.7yrs
Average Tenure
63yo
Average Age
Experienced Board: IART's board of directors are seasoned and experienced ( 11.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 17:32 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Integra LifeSciences Holdings Corporation is covered by 30 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Matthew Taylor | Barclays |
| Charley Jones | Barrington Research Associates, Inc. |